Neurocrine Biosciences to Present at the Canaccord Genuity 44th Annual Growth Conference

Rhea-AI Summary

Neurocrine Biosciences (NBIX) will present at the Canaccord Genuity 44th Annual Growth Conference in Boston on August 14, 2024, at 3:30 p.m. Eastern Time. Kyle Gano, Chief Business Development and Strategy Officer, and Todd Tushla, Vice President of Investor Relations, will represent the company. The presentation will be webcast live and accessible on Neurocrine's website, with a replay available for approximately one month.

Neurocrine Biosciences is a neuroscience-focused biopharmaceutical company dedicated to developing treatments for neurological, neuroendocrine, and neuropsychiatric disorders. Their portfolio includes FDA-approved treatments for tardive dyskinesia, Huntington's disease-associated chorea, endometriosis, and uterine fibroids. The company has a robust pipeline with multiple compounds in mid to late-phase clinical development.

SAN DIEGO, Aug. 7, 2024 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) will present at the Canaccord Genuity 44^th Annual Growth Conference in Boston at 3:30 p.m. Eastern Time on Wednesday, August 14, 2024. Kyle Gano, Chief Business Development and Strategy Officer, and Todd Tushla, Vice President of Investor Relations, will present at the conference.

The live presentation will be webcast and may be accessed on Neurocrine Biosciences' website under Investors at www.neurocrine.com. A replay of the webcast will be available on the website approximately one hour after the conclusion of the event and will be archived for approximately one month.

About Neurocrine Biosciences
Neurocrine Biosciences is a leading neuroscience-focused, biopharmaceutical company with a simple purpose: to relieve suffering for people with great needs, but few options. We are dedicated to discovering and developing life-changing treatments for patients with under-addressed neurological, neuroendocrine, and neuropsychiatric disorders. The company's diverse portfolio includes FDA-approved treatments for tardive dyskinesia, chorea associated with Huntington's disease, endometriosis* and uterine fibroids*, as well as a robust pipeline including multiple compounds in mid- to late-phase clinical development across our core therapeutic areas. For three decades, we have applied our unique insight into neuroscience and the interconnections between brain and body systems to treat complex conditions. We relentlessly pursue medicines to ease the burden of debilitating diseases and disorders, because you deserve brave science. For more information, visit neurocrine.com, and follow the company on LinkedIn, X (Formerly Twitter) and Facebook. (*in collaboration with AbbVie)

NEUROCRINE BIOSCIENCES, NEUROCRINE, and YOU DESERVE BRAVE SCIENCE are registered trademarks of Neurocrine Biosciences, Inc. The Neurocrine logo is a trademark of Neurocrine Biosciences, Inc.

View original content to download multimedia:https://www.prnewswire.com/news-releases/neurocrine-biosciences-to-present-at-the-canaccord-genuity-44th-annual-growth-conference-302217036.html

SOURCE Neurocrine Biosciences, Inc.

FAQ

When and where will Neurocrine Biosciences (NBIX) present at the Canaccord Genuity conference?

Neurocrine Biosciences (NBIX) will present at the Canaccord Genuity 44th Annual Growth Conference in Boston on August 14, 2024, at 3:30 p.m. Eastern Time.

Who will represent Neurocrine Biosciences (NBIX) at the Canaccord Genuity conference?

Kyle Gano, Chief Business Development and Strategy Officer, and Todd Tushla, Vice President of Investor Relations, will represent Neurocrine Biosciences (NBIX) at the conference.

How can investors access Neurocrine Biosciences' (NBIX) presentation at the Canaccord Genuity conference?

Investors can access the live webcast of Neurocrine Biosciences' (NBIX) presentation on the company's website under the Investors section at www.neurocrine.com.

What are some of the FDA-approved treatments in Neurocrine Biosciences' (NBIX) portfolio?

Neurocrine Biosciences' (NBIX) portfolio includes FDA-approved treatments for tardive dyskinesia, chorea associated with Huntington's disease, endometriosis, and uterine fibroids.

What is the main focus of Neurocrine Biosciences (NBIX) as a company?

Neurocrine Biosciences (NBIX) is a neuroscience-focused biopharmaceutical company dedicated to discovering and developing treatments for neurological, neuroendocrine, and neuropsychiatric disorders.